Championing Universal PMAD Screening in Obstetric Practice: A Data-Driven Approach

Selective screening misses cases at a rate that is no longer defensible to a partner meeting, a malpractice carrier, or a payer audit. The practice that screens "the patients who look depressed" identifies roughly 30 to 50 percent of perinatal mood and anxiety disorders (PMADs); universal screening with a validated tool identifies closer to 80 to 90 percent (Earls et al., 2019; ACOG Clinical Practice Guideline No. 4). The gap is not a matter of clinical skill. It is a structural property of how mood disorders present in prenatal and postpartum visits, where complaints are often somatic, sleep is already disrupted, and the chief complaint is almost never "I am depressed."

If you are the physician trying to move your group from selective to universal screening, your problem is rarely the clinical evidence. The evidence is settled. Your problem is partners who believe they already screen adequately, administrators who view it as scope creep, and a workflow that was not built to capture a structured score at every eligible visit. This piece gives you the data, the guideline language, and the documentation framework to close that gap.

The cost of selective screening, framed for a partner meeting

Start the internal case with missed cases, not recommendations. PMAD prevalence runs 10 to 20 percent during pregnancy and the first postpartum year, with higher rates in Medicaid and medically complex populations (Wisner et al., 2013; ACOG). For a practice delivering 1,200 births per year, that translates to roughly 150 to 240 affected patients annually. Selective screening at a 40 percent detection rate identifies 60 to 96 of them. Universal screening at 85 percent detection identifies 128 to 204. The delta, 60 to 100 undiagnosed PMADs per year per 1,200 deliveries, is the number partners need to see.

The downstream cost of those missed cases lands in three categories:

1. Patient outcomes. Untreated perinatal depression doubles the risk of preterm birth and low birth weight (Grote et al., 2010) and is the leading cause of pregnancy-related death in many states when suicide and overdose are included (CDC Pregnancy Mortality Surveillance, 2017 to 2019).
2. Liability exposure. Maternal suicide and infant harm cases increasingly name the obstetric practice when the chart shows no documented screen. Malpractice carriers including The Doctors Company and ProAssurance have published risk advisories citing undocumented PMAD screening as a named vulnerability.
3. Payer performance. HEDIS Prenatal and Postpartum Depression Screening measures (PND-E and PDS-E), along with the Postpartum Care measure (PPC-E), now feed value-based contracts in most commercial and Medicaid MCO arrangements. Practices in the bottom quartile lose quality bonuses; practices in the top quartile earn them.

Present those three categories with practice-specific numbers. Partner meetings move on dollars and named risk, not on aspirational framing.

ACOG guideline language: require vs. recommend

ACOG does not issue binding requirements on member practices; it issues clinical recommendations. That distinction gets weaponized in internal debates, so be precise about what the current guidelines actually say.

ACOG Clinical Practice Guideline No. 4 (2023), "Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum," recommends:

• Screening all patients for depression and anxiety at the initial prenatal visit
• Rescreening later in pregnancy
• Screening at the comprehensive postpartum visit
• Using a validated tool (EPDS, PHQ-9, GAD-7, or equivalent)

ACOG Practice Bulletin 343 and the related committee opinions reinforce that PMAD screening is a standard component of obstetric care, integrated into the 4-visit postpartum care model introduced in Committee Opinion 736 (reaffirmed 2021). That model replaces the single 6-week visit with contact points at 1 to 3 weeks, a 3 to 8 week visit, a comprehensive visit by 12 weeks, and as-needed interval contacts. Each contact is a screening opportunity.

The USPSTF Grade B recommendation for perinatal depression screening does create a functional requirement: under ACA Section 2713, commercial plans must cover Grade A and B preventive services without cost-sharing. Payers code against this. A practice that fails to document screening forgoes a reimbursable service and increases the risk that a payer audit treats the omission as a quality failure.

The advocacy line for a resistant partner: ACOG recommends, USPSTF effectively mandates coverage, HEDIS measures performance, and malpractice carriers now cite screening gaps in risk advisories. Four independent bodies converge on the same standard.

"We already screen some patients": the denominator problem

The most common internal objection is that the practice already screens when indicated. Push on the word "indicated." Selective screening rests on clinician gestalt, which the literature shows performs at roughly chance for subclinical and moderate presentations. More importantly, "we already screen" almost never survives a denominator.

Run this report from the EHR, or ask the QI nurse to run it:

• Numerator: unique patients with a documented EPDS or PHQ-9 score during the measurement period
• Denominator: unique patients with at least one eligible prenatal visit (for PND-E) or at least one postpartum visit within 1 to 12 weeks of delivery (for PDS-E / PPC-E)
• Window: rolling 12 months

Report the rate, the raw numbers, and the gap against HEDIS 90th percentile. Practices that self-describe as "already screening" typically land at 30 to 55 percent documented against a HEDIS 90th percentile that now exceeds 75 percent in commercial lines and 60 percent in Medicaid (NCQA Quality Compass, 2024). The number does the argument for you.

If the EHR does not pull a clean HEDIS-aligned report, that is itself the finding. A screening rate that cannot be measured is a screening rate that cannot be defended to a payer or a plaintiff's attorney.

Liability reduction and HEDIS performance as aligned levers

Universal screening improves two metrics that partners and administrators both track: malpractice risk and quality contract performance. Frame the two together.

On liability: documented universal screening creates an affirmative defense. The chart shows the score, the clinical decision, and the referral. Selective screening creates a documentation pattern where some charts show scores and others do not, which is harder to defend than consistent universal screening with occasional declines documented.

On HEDIS: PND-E, PDS-E, and PPC-E feed directly into commercial and Medicaid value-based payment arrangements. The PPC-E denominator includes a postpartum depression screen within the postpartum care measure. A practice that moves from 40 to 75 percent documented screening typically moves one or two quality tiers in its MCO contracts, which shows up as real per-member-per-month dollars at the next contract cycle.

The champion's talking point: the same workflow change improves the carrier's risk profile and the practice's payer scorecard. There is no strategic tension between the two.

Champion documentation: a QI log that survives audit

Partner buy-in is necessary but not sufficient. The champion role fails when activities are not documented, because MOC Part IV credit, malpractice premium credits, and internal QI reporting all require evidence.

A defensible champion file contains:

• Protocol document. One page, signed and dated, naming screening tool, cadence (initial prenatal, third trimester, postpartum 1 to 3 weeks, postpartum comprehensive), cutoff score, and escalation pathway.
• Workflow diagram. Who administers the tool, who scores it, where the score lands in the EHR, what triggers a warm handoff, and what the referral list is.
• Monthly screening rate report. EHR-pulled, HEDIS-aligned, reviewed in staff meeting, retained for at least 3 years.
• Meeting minutes. Any meeting where the protocol, rate, or referral pathway is discussed, with attendees and action items.
• Training records. Dates, attendees, and materials for any staff training on the screening tool, the escalation pathway, or suicide risk response.
• Referral log. Patients with positive screens and confirmed handoff to behavioral health, with date and receiving clinician.

Store this in a shared drive folder named by year. When the malpractice carrier asks for a risk management attestation, or the ACGME site visitor asks for QI evidence, or the hospital credentials committee asks for MOC Part IV documentation, the folder answers all three.

Where to find practice-level benchmarks

Credible benchmarks come from four sources:

1. NCQA Quality Compass. National and regional HEDIS rates for PND-E, PDS-E, and PPC-E, stratified by commercial, Medicaid, and Medicare lines. Available by subscription; most health system QI offices hold a license.
2. State Medicaid quality reports. Most state Medicaid agencies publish annual MCO quality reports that include plan-level PPC-E and prenatal depression screening rates. These are free and searchable on state Medicaid websites.
3. Perinatal Quality Collaboratives (PQCs). More than 30 states operate PQCs, many of which run PMAD-specific initiatives with de-identified practice-level rate sharing. The CDC maintains a directory.
4. Internal EHR reports against HEDIS specifications. Epic, Cerner, and athenahealth all publish HEDIS-aligned report templates. Align your numerator and denominator to the NCQA spec so your internal number is comparable to the external benchmark.

When you present a benchmark to partners, lead with the practice's own rate, then the state Medicaid MCO median, then the HEDIS 90th percentile. That ordering shows the gap without inviting debate over which benchmark is "fair."

Moving a practice from selective to universal: a 90-day sequence

The champion's work collapses to a short, defensible sequence:

• Days 1 to 15. Pull baseline HEDIS-aligned screening rate. Present to partners with missed-case math and malpractice carrier advisory. Do not ask for a vote; ask for a pilot.
• Days 16 to 45. Stand up the protocol, the workflow diagram, and the EHR changes. Train MAs or RNs to administer and score. Establish the referral list and the warm handoff contact.
• Days 46 to 75. Run the workflow. Track weekly screening completion at the rooming step, not at the visit-end step, where it fails. Troubleshoot documentation gaps.
• Days 76 to 90. Pull a fresh HEDIS rate. Compare to baseline. Present to partners with referral volume, positive-screen rate, and handoff success rate.

A practice that executes this sequence typically moves screening rate 25 to 40 percentage points in 90 days. Partners who voted against it in month one generally vote to make it policy in month four, because the data makes the argument the champion was making verbally.

The clinical evidence, the payer incentives, and the liability environment all point the same direction. The remaining work is internal, structural, and documentable. That is the champion's job.

---

Interested in setting up a referral pathway or discussing collaborative care?

We work with OB practices, pediatric offices, and hospital systems to build seamless referral workflows. Start a partnership conversation.

Sources

• ACOG Clinical Practice Guideline No. 4: Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (2023)
• ACOG Practice Bulletin 343: Psychiatric Medication Use During Pregnancy and Lactation
• ACOG Committee Opinion 736: Optimizing Postpartum Care (reaffirmed 2021)
• USPSTF Final Recommendation Statement: Depression and Suicide Risk in Adults, Screening (2023); Perinatal Depression, Preventive Interventions (2019, Grade B)
• NCQA HEDIS Measures: PND-E (Prenatal Depression Screening and Follow-Up), PDS-E (Postpartum Depression Screening and Follow-Up), PPC-E (Prenatal and Postpartum Care)
• Earls MF, Yogman MW, Mattson G, Rafferty J; AAP Committee on Psychosocial Aspects of Child and Family Health. Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice. Pediatrics. 2019
• Wisner KL, et al. Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression Findings. JAMA Psychiatry. 2013
• Grote NK, et al. A Meta-analysis of Depression During Pregnancy and the Risk of Preterm Birth, Low Birth Weight, and Intrauterine Growth Restriction. Archives of General Psychiatry. 2010
• CDC Pregnancy Mortality Surveillance System, 2017 to 2019